Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EBIT (2024 - 2025)

Historic EBIT for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to -$4.1 million.

  • Neuphoria Therapeutics' EBIT fell 964.77% to -$4.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.6 million, marking a year-over-year change of. This contributed to the annual value of -$1.1 million for FY2025, which is 9368.95% up from last year.
  • According to the latest figures from Q4 2025, Neuphoria Therapeutics' EBIT is -$4.1 million, which was down 964.77% from -$5.7 million recorded in Q3 2025.
  • In the past 5 years, Neuphoria Therapeutics' EBIT ranged from a high of $12.0 million in Q1 2025 and a low of -$5.8 million during Q2 2025